1 - Rapezzi C, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398-408.
2 - Ruberg FL, et al. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286-1300
3 - Eloisa Arbustini, Antonello Gavazzi, Giampaolo Merlini, Proteine che "fibrillano": l'amiloidosi. Nuove speranze per una malattia che il cardiologo deve conoscere - G Ital Cardiol 2002;3(6):590-597
4 - Rapezzi C, Quarta CC, Obici L et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013; 34:520-8
5 - Jose Nativi-Nicolau , Mathew S Maurer - Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018;33(5):571-579.
6 - American Heart Association. Answers by Heart. Cardiovascular Conditions. 2019. Available at: https://www.heart.org/-/media/files/health-topics/answers-by-heart/what-is-attrcm.pdf. Accessed November 2021.
7 - Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart 2012;98:1546-54.
8 - Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 27;112:2047-60 4.
9 - Ando Y, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orph J of Rare Diseases. 2013;8:31.
10 - Gillmore JD, Maurer MS, Falk RH, et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412.
11 - Gendre T., Planté-Bordeneuve V. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy. Clin Auton Res. 2019; 29 (Suppl 1): 25-31
12 - Legge 502, 1992 - Allegato 7. Supplemento ordinario n°15 alla Gazzetta Ufficiale, Serie Generale - n°65
13 - Definizione e aggiornamento dei livelli essenziali di assistenza, di cui all'articolo 1, comma 7, del decreto legislativo 30 dicembre 1992, n°502 (17A02015)
14 - Decreto legislativo 29 aprile 1998, n°124
|
|
